ADC Therapeutics SA - Q2 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. ADC Therapeutics SA is a commercial-stage biopharmaceutical company focused on antibody drug conjugates (ADCs). Its primary revenue-generating asset is ZYNLONTA (loncastuximab tesirine-lpyl), approved for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The company is also advancing a next-generation PSMA-targeting ADC. During the quarter, the Board approved a strategic restructuring plan to focus resources on ZYNLONTA expansion and the PSMA program, discontinuing other early-stage solid tumor programs.
Key Financial Metrics
| Metric (in thousands) | Q2 2025 | Q2 2024 | YTD 2025 | YTD 2024 |
|---|---|---|---|---|
| Total Revenue | $18,839 | $17,410 | $41,872 | $35,463 |
| Net Loss | $(56,646) | $(36,544) | $(95,248) | $(83,150) |
| Net Loss Per Share | $(0.50) | $(0.38) | $(0.86) | $(0.93) |
| Cash and Equivalents (End of Period) | $264,560 | $300,119 | $264,560 | $300,119 |
| Operating Cash Flow (YTD) | $(80,421) | $(76,940) | $(80,421) | $(76,940) |
| Senior Secured Term Loans | $114,473 | $113,632 | $114,473 | $113,632 |
| Deferred Royalty Obligation | $333,244 | $320,093 | $333,244 | $320,093 |
Note: Margins are not applicable as the company is in a net loss position. Gross profit for Q2 2025 was $17.2 million (91.4% margin) before restructuring costs.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 8.2% QoQ and 18.1% YoY (YTD). Product revenue grew 6.2% QoQ due to higher pricing and volume. License revenue surged due to a $5.0 million milestone payment from Sobi following Health Canada's conditional approval of ZYNLONTA.
- Restructuring Costs: The company incurred $13.1 million in restructuring, impairment, and other related costs in Q2 2025 (none in Q2 2024). This included $6.7 million in severance and $6.4 million in non-cash impairments related to the closure of the UK facility and workforce reduction.
- Operating Expenses: R&D expenses increased 23.9% QoQ, driven by clinical trial enrollment (LOTIS-5 and LOTIS-7) and IND-enabling activities for the PSMA-targeting ADC. Selling and marketing and G&A expenses decreased due to cost-cutting initiatives.
- Financing Activity: In June 2025, the company completed a private placement raising $100.0 million gross ($93.1 million net) through the sale of common shares and pre-funded warrants.
Guidance, Outlook, and Risks
- Strategic Reprioritization: Management is executing a restructuring plan to reduce the global workforce by approximately 30% and shut down the UK R&D facility, with completion expected by September 30, 2025. Resources are being redirected to ZYNLONTA expansion and the PSMA-targeting ADC.
- Liquidity: As of June 30, 2025, the company held $264.6 million in cash. Management believes this is sufficient to fund operations for at least the next 12 months.
- Regulatory and Tax Risks: The company is evaluating the impact of the U.S. "One Big Beautiful Bill" (H.R. 1) passed in July 2025, which includes changes to R&D capitalization and interest deductions. Additionally, potential U.S. tariffs on imported drugs and "Most Favored Nation" pricing policies pose risks to future revenue.
- Debt Obligations: The company carries significant interest expense ($13.0 million in Q2) primarily from the accretion of the deferred royalty obligation with HCR and the senior secured term loan facility.
Key Investor Verification Points
- Restructuring Execution: Verify the timeline and cost savings associated with the UK facility closure and 30% workforce reduction.
- Cash Burn Rate: Monitor operating cash flow usage against the $264.6 million cash balance to confirm the 12-month runway.
- ZYNLONTA Commercialization: Track gross-to-net sales adjustments and patient enrollment in the LOTIS-5 and LOTIS-7 trials to assess revenue sustainability.
- Debt Service: Review the impact of the $333.2 million deferred royalty obligation and $114.5 million term loan on future liquidity and interest expenses.
- Regulatory Impact: Assess the financial implications of the new U.S. tax legislation (H.R. 1) and potential drug pricing reforms.